AzTrials
AzTrials

Enhanced Recovery After Surgery in a Pediatric PopulationPhase 1/2NCT06538584

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population

A Phase 1/2 study testing Caffeine citrate 15mg/kg and 0.9% Sodium Citrate in people with Enhanced Recovery After Surgery in a Pediatric Population, run by University of Chicago at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Dexmedetomidine (Dex), a selective α2-adrenergic receptor agonist, is the most used sedative for procedural sedation in children and in pediatric Intensive Care Unit (PICU) because it is associated with less respiratory depression and also less neurotoxicity; rather Dex appears neuroprotective. Read more about this study

Who is it for?
Ages 3 to 12 yearsHealthy volunteers can take part
What is being tested?
Caffeine citrate 15mg/kg and 0.9% Sodium Citrate
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
100 participants
Where
1 siteUnited States
Study dates
9 Sep 2024to 31 Dec 2027
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 12 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Undergo Magnetic Resonance Imaging (MRI) scan
  • Age ≥3 and ≤ 12 yr old
  • Both Male and Female
  • Weight ≤33.3 kg
  • American Society of Anesthesiologists ASA) physical status 1-3
  • No History of Arrhythmia (3-leads Electrocardiogram [EKG] applied before and after the sedation) or congenital heart disease
Show all 11Show fewer
  • Capable of obtaining consent from at least one parent
  • No history of liver and kidney impairment
  • No history of head trauma
  • No prior history of difficulty with anesthesia
  • No personal or family history of malignant hyperthermia

Who cannot join

  • Age <3 or >12
  • Weight >33.3 kg
  • ASA physical status > 3
  • History Arrhythmia, congenital heart disease, liver, and kidney diseases
  • Prior difficulty with anesthesia
  • Personal or family history of malignant hyperthermia
Show all 9Show fewer
  • Unable to obtain consent
  • History of head trauma
  • Female subjects who are pregnant

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Zheng Xie, MD, PhD contact

773-702-2667

jxie@bsd.uchicago.edu

United States1 site, 1 recruiting
  • University of Chicago Medical Center

    Chicago, Illinois, 60637

    Zheng (Jimmy) Xie, MD, PhD, 773-702-2667, JXie@dacc.uchicago.edu

    Aaron Fox, PhD, 773-702-0021, afox@bsd.uchicago.edu

    Recruiting

Other trials in United States

About this study

Official title: Caffeine Facilitates the Recovery of Dexmedetomidine Sedation for MRI in Pediatric Patients: a Randomized, Double-blinded and Placebo-controlled Pilot Study

Dexmedetomidine (Dex), a selective α2-adrenergic receptor agonist, is the most used sedative for procedural sedation in children and in pediatric Intensive Care Unit (PICU) because it is associated with less respiratory depression and also less neurotoxicity; rather Dex appears neuroprotective. Unfortunately, Dex is associated with very long emergence times and may cause bradycardia and hypotension. However, using sedation dosing guidelines (by consensus among SPS members) 1-3 mcg/kg bolus and a 1-2 mcg/kg/hour infusion, hemodynamic compromise is less significant and rarely requires intervention in these patients. With this Dex sedation protocol, these pediatric patients usually take an average of 45 minutes (30-60 minutes) to wake and become alert and up to 2 hours to be discharged.

Without reversal agents, emergence times from Dex sedation are slow. The prolonged recovery after Dex sedation for non-surgical procedures negatively affects throughput, thus increasing the cost of care. Patient safety and satisfaction suffer as a result. The children wake feeling tired and sluggish. The children don't feel back to normal for an extended period of time, which is not surprising given that the half-life for Dex metabolism in 2-3 hours in humans. However, using sedation dosing guidelines (by consensus among SPS members) 1-3 mcg/kg bolus and a 1-2 mcg/kg/hour infusion, hemodynamic compromise is less significant and rarely requires intervention in these patients. In humans, it has been found that caffeine at 7.5 mg/kg (15 mg caffeine citrate equivalent to 7.5 mg caffeine base) sped emergence from isoflurane anesthesia with minimal hemodynamic effects in healthy human volunteers.

The goal of this clinical trial is to determine whether caffeine will facilitate the recovery of Dex sedation after a Magnetic Resonance Imaging (MRI) procedure by measuring the time from the end of Dex infusion to the time meeting the discharge criteria.

Read the detailed description

SCREENING DAY (-1-3) - PRIOR TO APPOINTMENT Only a single visit will take place prior to the MRI scan procedure. This will be done one to three days prior to the sedation procedure, via chart screening or on the day of the sedation and MRI procedure if the advanced review is not possible.

Once potentially appropriate subjects have been identified from the OR schedule for the next day, the study team will contact the anesthesia provider (resident, CRNA, attending) who is scheduled to treat that patient and explain to him/her about the research project and ask them to use a Sedline Brain Function Monitor for the case.

  • Sedation team calls patient family with reminder about appointment and NPO instructions.
  • Research pharmacy notified about potential patients.

DAY 0 - APPOINTMENT DAY On the day of the Magnetic Resonance Imaging (MRI) procedure in the preoperative holding area.

  • Study consent or/and assent obtained by study team in the pre-sedation area.
  • Study team notifies research pharmacy to prepare/deliver study drug

PRE-SEDATION

  • Patient arrives in sedation suite
  • RN rooms patient, obtains vitals (height, weight, heart rate, respiratory rate, blood pressure, 3-lead electrocardiogram [EKG], and temperature), reviews allergies, and asks health-related questions
  • Physician (MD) called to room to complete patient history, physical examination, and review/sign sedation consent
  • Sedation physician reviews sedation plan with nurse
  • The sedation physician will be delegated by the Principal Investigator (PI) and be Institutional Review Board (IRB)-approved on this study to provide the study drug
  • Sedation physician enters H+P/orders while nurse starts the peripheral IV (PIV) and prepares sedation medication
  • Sedation physician returns to bedside for induction In explaining the research project to anesthesia providers, the study team will stress the importance of keeping the patient's Sedline Density Spectral Array (DSA) between 8-15 or/and Patient State Index (PSI) reading between 25-50 throughout the course of the case in the subjects who are randomly selected in the monitoring group. If BP or HR is over 25-30 % baseline, an opioid or other pain medications will be used first, before increasing the dose of inhalational agent or propofol. If BP is low and PSI is on the low end, study team will lower the inhalational agent or propofol first. If the patient moves and BP and PSI are within the ranges, muscle relaxant may be given first unless the use of muscle relaxant is not allowed for the surgical reason. If both opioids and muscle relaxant adjustment fail to achieve the hemodynamic stability and immobility goal, then the study team will adjust the doses of inhalational agent or propofol.
  • Time out performed

SEDATION The anesthesia provider will apply a Sedline Monitor to their forehead during the general anesthesia procedure. The anesthesia provider may use the data from the monitor to affect their anesthetic administration, or may cover the data from the monitor and only use conventional measures to guide anesthetic dosing in these control cases (blood pressure, heart rate, body movement, respiratory rate, MAC of inhalational agent), depending on what group into which the patient has been randomized.

  • Start induction with Dex (3mcg/kg bolus of dexmedetomidine over 10 minutes, followed by a Dex infusion of 2mcg/kg/minute)
  • Nasal cannula with ETCO2 placed
  • Transport checklist (O2 tank full, Bag mask at head of bed, Airway bag, meds, transport monitor with battery, suction, emergency med bag) completed *only if MRI outside of Comer
  • Patient transported to MRI
  • Patient is placed on MRI table, monitors switched for MRI compatible monitors If additional medication is required for induction or movement artifact on MRI imaging, propofol bolus(es) or, in rare cases, fentanyl bolus(es), may be given as needed per standard sedation protocol. All sedation medications are documented in the medical record per protocol.

If BP or HR is over 25-30 % baseline, an opioid or other pain medications will be used first, before increasing the dose of inhalational agent or propofol. If BP is low and PSI is on the low end, study team will lower the inhalational agent or propofol first. If the patient moves and BP and PSI are within the ranges, muscle relaxant may be given first unless the use of muscle relaxant is not allowed for the surgical reason. If both opioids and muscle relaxant adjustment fail to achieve the hemodynamic stability and immobility goal, then the study team will adjust the doses of inhalational agent or propofol.

  • MRI Scan completed
  • Dex stopped and the time recorded. Dex infusion should continue until MRI completion, but weaning of Dex is allowed if deemed clinically appropriate. Weaning of Dex will be documented in the medical record as per sedation protocol.

RECOVERY

  • After MRI is completed, patient is placed back on transport bed and monitors exchanged for transport monitors
  • Patient transported back to sedation suite for recovery
  • Sedline monitor is placed on patient.
  • After 2-3 minutes of recording, patient receives study drug (caffeine citrate/placebo) at 10mL/kg over 5 minutes.
  • Registered Nurse (RN) monitors patient per routine sedation protocol (every 5min vitals, Patient Sedation State Score [PSSS] score)
  • Study team records time to awake
  • Sedline monitor may be removed after patient is awake Once the general anesthesia procedure is over and the patient is recovering in PICU, the study team will meet with each patient and parent again, and use a standardized survey to ask about their satisfaction with their anesthetic, including questions about their post-operative pain and feelings of nausea or presence of vomiting. They should also be awake, be able to drink clear liquid, void and ambulate before discharge home with their parents.
  • Study team records time to meet discharge criteria
  • Patient discharged per routine protocol

FOLLOW-UP DAY 1 AFTER SEDATED MRI

  • Patient receives call from sedation scheduler the next day per sedation team protocol
  • Patient receives call from study team the next day via the standardized post-operative survey The study team will follow-up the next day with each patient's parent via phone call and ask the same survey questions to ensure resolution of their symptoms and timing of the resolution of their symptoms..
Being tested
Caffeine citrate 15mg/kg, 0.9% Sodium Citrate
Keywords
Dexmedetomidine sedation, Caffeine citrate stimulant, Pediatric surgical population

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Caffeine citrate 15mg/kgDrug

    Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 15mg/kg Caffeine citrate 15 minutes post surgery.

  • 0.9% Sodium CitrateDrug

    Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.

Study groups in NCT06538584
Study groupRoleWhat they receive
Dexmedetomidine +/- Caffeine SedationExperimentalEligible subjects will be given 15 mg/kg caffeine citrate (equivalent to ~5 mg/ kg caffeine base) ~ 15 min after terminating Dex's infusion.
Receives: Drug: Caffeine citrate 15mg/kg
Dexmedetomidine +/- Placebo SedationPlacebo comparatorEligible subjects will be given 9 mg/ml saline placebo) ~ 15 min after terminating Dex's infusion.
Receives: Drug: 0.9% Sodium Citrate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improve rate of wakefulness post surgery

    Subject post-surgery wakefulness recovery with caffeine based on a modified Aldrete score

    Measured: Up to 2 hours

Secondary outcomes (1)
  1. Time needed to be able to return to tasks performance with purpose

    Eyes open, normal response to verbal stimulation, crying/complaining, taking PO (if applicable)

    Measured: Up to 2 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2024
  2. Study start9 Sep 2024
  3. Primary completion1 Jul 2026 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
A randomized model with 2 arms/interventions consisting of caffeine v. saline placebo
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06538584
Sponsor's protocol ID
IRB24-0210
Status last verified
Sep 2025
First submitted
1 Aug 2024
Last updated
12 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Xie Z, Fong R, Fox AP. Towards a potent and rapidly reversible Dexmedetomidine-based general anesthetic. PLoS One. 2023 Sep 26;18(9):e0291827. doi: 10.1371/journal.pone.0291827. eCollection 2023.

    PubMed 37751454
  • Xie Z, Fox AP. Rapid emergence from dexmedetomidine sedation in Sprague Dawley rats by repurposing an alpha2-adrenergic receptor competitive antagonist in combination with caffeine. BMC Anesthesiol. 2023 Feb 1;23(1):39. doi: 10.1186/s12871-023-01986-5.

    PubMed 36721095
  • Fong R, Wang L, Zacny JP, Khokhar S, Apfelbaum JL, Fox AP, Xie Z. Caffeine Accelerates Emergence from Isoflurane Anesthesia in Humans: A Randomized, Double-blind, Crossover Study. Anesthesiology. 2018 Nov;129(5):912-920. doi: 10.1097/ALN.0000000000002367.

    PubMed 30044241
  • Mason KP, Lerman J. Review article: Dexmedetomidine in children: current knowledge and future applications. Anesth Analg. 2011 Nov;113(5):1129-42. doi: 10.1213/ANE.0b013e31822b8629. Epub 2011 Aug 4.

    PubMed 21821507

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Caffeine citrate 15mg/kg and 0.9% Sodium Citrate in people with Enhanced Recovery After Surgery in a Pediatric Population, run by University of Chicago at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Zheng Xie, MD, PhD (773-702-2667, jxie@bsd.uchicago.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improve rate of wakefulness post surgery (time frame: Up to 2 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06538584, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in